Present and future in vitro approaches for drug metabolism

Journal of Pharmacological and Toxicological Methods

Volumn 44, Issue 1, 2000, Pages 313-324

  Ekins, Sean ^a   Ring, Barbara J ^a   Grace, James ^a   McRobie Belle, Donna J ^a   Wrighton, Steven A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cytochrome P450; In vitro; Metabolism

Indexed keywords

CYTOCHROME P450;

ARTICLE; CELL FRACTIONATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; IN VITRO STUDY; LIVER CELL; NONHUMAN; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION; VALIDATION PROCESS;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INDUSTRY; DRUG INTERACTIONS; HEPATOCYTES; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS;

EID: 0034458681     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(00)00110-6     Document Type: Article

References (142)

1. Population pharmacokinetics: Theory and practice
2. Demethylation and methylation of drugs and physiologically active compounds
3. The use of tissue slices for pharmacotoxicology studies
4. Liver slices in dynamic organ culture: I. An alternative in vitro technique for the study of rat hepatic drug metabolism
5. Liver slices in dynamic organ culture: II. An in vitro cellular technique for the study of integrated drug metabolism using human tissue
6. Reforming the patent system
7. High-yield preparation of isolated rat liver parenchymal cells
8. Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyl-transferases
9. Usefulness of statistic experimental designs in enzymology: Example with recombinant hCYP3A4 and 1A2
10. Virtual kinetics: Using statistical experimental design for rapid analysis of enzyme inhibitor mechanisms
11. Sparse sampling for assessment of drug exposure in toxicological studies
12. Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450
13. cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus
14. Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes
15. Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe
16. Validation of higher-throughput high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry assays to conduct cytochrome P450s CYP2D6 and CYP3A4 enzyme inhibition studies in human liver microsomes
17. Microtiter plate assays for inhibition of human drug-metabolizing cytochromes P450
18. High throughput screening for inhibition of cytochrome P450 metabolism
19. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions
20. A commentary on the use of hepatocytes in drug metabolism studies during drug discovery and development
21. Concomitant toxicokinetics: Techniques for and interpretation of exposure data obtained during the conduct of toxicology studies
22. Structure-function analysis of human cytochrome P-450 2B6 using novel substrate, site-directed mutagenesis, and molecular modeling
23. Drug-drug interactions related to hospital admissions in older adults: A prospective study of 1000 patients
24. Advances in in vitro drug metabolism screening
25. Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism
26. In vitro metabolism: Subcellular fractions
27. Autoactivation and activation of cytochrome P450s
28. Predicting drug-drug interactions in silico using pharmacophores: A paradigm for the next millenium
29. Examination of purported probes of human CYP2B6
30. The role of CYP2B6 in human xenobiotic metabolism
31. Long-term primary cultures of adult human hepatocytes
32. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethacin
33. Amino acid 305 determines catalytic center assessibility in CYP3A4
34. Merits and limitations of recombinant models for the study of human P450-mediated drug metabolism and toxicity: An intralaboratory comparison
35. Systematic screening for pharmacokinetic interactions during drug development
36. Use of precision-cut liver slices as an in vitro tool for evaluating liver function
37. Oxidation and reduction by microsomal enzymes
38. Use of fresh and cryopreserved human liver slices in toxicology with special reference to in vitro induction of cytochrome P450
39. The study of xenobiotic-metabolizing enzymes and their role in toxicity in vivo using targeted gene disruption
40. Role of gene knockout mice in understanding the mechanisms of chemical toxicity and carcenogenesis
41. Influence of alginate gel entrapment and cryopreservation on survival and xenobiotic metabolism capacity of rat hepatocytes
42. Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction
43. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities
44. Testefenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences
45. A high throughput screening assay for CYP3A4 interactions using SPA
46. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model
47. Alterations in the catalytic activities of drug metabolizing enzymes in long-term cultures of precision-cut rat liver slices
48. Single point screening for high throughput methods to predict drug-drug interaction potential
49. i in a competitive enzyme-inhibition model: Comparisons among three methods of data analysis
50. Managing the discovery/development interface
51. HPLC-API/MS/MS: A powerful tool for integrating drug metabolism into the drug discovery process
52. Evaluation of atypical cytochrome P450 kinetics with two-substrate-models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites
53. A new instrument for the rapid preparation of tissue slices
54. Preclinical evaluation of drug-drug interaction potential: Present status of the application of primary hepatocytes in the evaluation of cytochrome P450 induction
55. Inhibition of cytochrome P-450 and implications in drug development
56. Automation of metabolic stability studies in microsomes, cytosol and plasma using a 215 Gilson liquid handler
57. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
58. Role of hemoprotein P-450 in fatty acid ω-hydroxylation in a soluble enzyme system from liver microsomes
59. Resolution of the cytochrome P-450-containing ω-hydroxylation system of liver microsomes into three components
60. Experimental design for high-throughput screening
61. Human cytochrome P4503A (CYP3A) mediated midazolam metabolism: The effect of assay conditions and regioselective stimulation by a-napthoflavone, terfenadine and testosterone
62. Characterisation of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates
63. A population approach toenzyme characterization and identification: Application to phenacetin O-deethylation
64. Torsades de pointes occurring in association with terfenadine use
65. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: Assessment of human CYP inhibition potential
66. The 450 superfamily: Update on new sequences, gene mapping, and recommended nonmenclature
67. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
68. The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations
69. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and non specific binding to microsomes
70. Expression of rat liver cytochrome P-450mc cDNA in Saccharomyces cerevisiae
71. Liver slices in in vitro pharmacology with special reference to the use of human liver tissue
72. Selection and characterization of human cytochrome P450 1A2 mutants with altered catalytic properties
73. Understanding consequences of concurrent therapies
74. A method for estimating pharmacokinetic risks of concentration-dependent drug interactions from preclinical data
75. Effect of some indole derivatives on xenobiotic metabolism and xenobiotic induced toxicity in cultured rat liver slices
76. Preclinical drug metabolism in the age of high-throughput screening: An industrial perspective
77. Rational high-throughput screening in preclinical drug metabolism
78. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6)
79. Preparation of isolated rat liver cells
80. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey
81. Forescasting individual pharmacokinetics
82. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
83. In vitro metabolism: Hepatocytes
84. Design of signal windows in high throughput screening assays for drug discovery
85. Human cytochrome P450s: Selectivity and measurement in vivo
86. Dynamic organ culture of precision liver slices for in vitro toxicology
87. Comparison of human and rhesus monkey in vitro phase I and phase II hepatic drug metabolism activities
88. The rational selection of drug interaction studies: Implications of recent advances in drug metabolism
89. Alterations in the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices
90. Cytochrome P-450 purified to apparent homogeneity from phenobarbital-induced rabbit liver microsomes: Catalytic activity and other properties
91. Xenobiotic metabolism in precision-cut dynamic organ cultured human liver slices
92. Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent
93. Heterologous expression of cytochrome P-450 in Escherichia coli
94. Metabolite kinetics of ondansetron in rat. Comparison of hepatic microsomes, isolated hepatocytes and liver slices, with in vivo disposition
95. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine
96. The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies
97. The human hepatic cytochromes P450 involved in drug metabolism
98. In vitro methods for assessing human hepatic drug metabolism: Their use in drug development
99. Assessment of potential interactions between dopamine agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen
100. Automated high throughput human CYP isoform activity using SPE-LC/MS method: Application in CYP inhibition evaluation